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Treatment of hypertension after renal transplantation: Long-
term efficacy of verapamil, enalapril, and doxazosin. Normal
blood pressure is a good marker of graft survival after renal
transplantation, and effective antihypertensive treatment reduces
the progression of graft damage. We conducted a long-term
follow-up study of 88 hypertensive renal transplant recipients, all
of whom were taking sustained cyclosporine A (CsA) immuno-
suppression. The patients were treated for at least three years, and
initially received 240 mg/day of verapamil (N 5 24, group I), 5
mg/day of enalapril (N 5 24, group II) or 1 mg/day of doxazosin
(N 5 40, group III). Baseline creatinine did not differ in the three
groups, but proteinuria was higher in the enalapril group (7
patients had proteinuria .1.5 g/day). Treatment was withdrawn in
5 patients in the verapamil group, 5 in the enalapril group and 2
in the doxazosin group due to drug-related side effects. Blood
pressure (BP) control at three years was equivalent in the three
groups (systolic BP, group I 157 6 12; group II 149 6 19; group
III 154 6 21; diastolic BP, group I 90 6 8.7, group II 84 6 9.8,
group III 90.5 6 16; mean BP, group I 113 6 7, group II 106 6 10,
group III 106 6 29). Two patients in group I, 3 in group II and 15
in group III required additional antihypertensive drugs. CsA
levels increased in the verapamil-treated patients, allowing for an
early decrease in CsA doses (1 year doses, 3.3 6 1 mg/kg body
wt/day in group I, 4.3 6 1.6 in group II, 3.7 6 1.6 in group III). Six
cardiovascular events occurred, 3 in group I, 1 in group II, and 2
in group III patients. One patient died in the enalapril group and
another in the doxazosin group. Eight verapamil-treated patients,
8 enalapril-treated patients and 4 doxazosin-treated patients lost
their grafts due to biopsy-proven chronic transplant nephropathy.
In conclusion, the three antihypertensive agents are effective in
reducing blood pressure, with no clear advantage of one above
any other. Verapamil allows the CsA dose to be reduced, thus
decreasing the cost of immunosupression. Enalapril can be a more
effective antiproteinuric agent, but hyperkalemia or impaired
allograft function may occur in patients with non-optimal allograft
function. Doxazosin offers an excellent safety and efficacy profile,
and when not efficient by itself in controlling blood pressure, is an
ideal concomitant agent in hypertensive renal transplant patients.
Hypertension after renal transplantation is an important
factor in cardiovascular mortality in children and adults
alike [1, 2], as well as a risk factor for graft loss [3]. It has
not been established whether this is due to the deleterious
effect of hypertension on the graft or if hypertension is a
marker of an underlying disease [3].
The incidence of hypertension in the pre-cyclosporine
era is estimated to be 40 to 50% of the renal transplant
recipients [4, 5]. Introduction of cyclosporine has increased
the prevalence of hypertension in the recipients of a solid
organ transplant, which ranges from 60% to 80% of renal
transplant patients, and up to 90% of non-renal transplant
patients [6, 7]. Comparing the incidence of hypertension in
patients treated with cyclosporine and azathioprine, Jaro-
wenko et al found that the prevalence of hypertension was
63% in patients treated with cyclosporine versus 42% in the
azathioprine group [6]. In the Cambridge University study
[7], the incidence of hypertension was 67% in cyclosporine-
treated patients versus 46% in azathioprine-treated pa-
tients. After switching from cyclosporine to azathioprine,
the incidence of hypertension decreased significantly.
Post-transplant hypertension has multiple causes and
mechanisms [8]. Usually, patients have more than one of
the identified causes of hypertension, and some patients
have all of the known causes [9]. In the early post-
transplant period, a positive imbalance of sodium and
water, acute tubular necrosis, acute ureteral obstruction,
acute rejection episodes, high steroid doses, renal artery
stenosis or hypercalcemia are factors that have been impli-
cated in the early production of hypertension [10].
Hypertension after the three first months of transplan-
tation may have other different causes. Steroids [11],
cyclosporine nephrotoxicity [12] and tacrolimus [13] have
been implicated as significant hypertensive factors. Steroid
reduction to less than 10 mg/day, alternate day dosing or
total steroid withdrawal [11] have decreased the incidence
of hypertension.
After the introduction of cyclosporine, chronic rejection
has persisted as an important factor for graft losses. The
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transplanted renal mass or minor differences between the
donor and recipient’s body surface area have been reported
as predictive factors for the development of chronic trans-
plant nephropathy and post-transplant hypertension [14].
Renal artery stenosis [8, 9], renin-dependent hyperten-
sion [15] and de novo or recurrent nephropathies are
responsible for some cases of post-transplant hypertension.
A kidney transplanted from a cadaveric donor with familial
essential hypertension can induce post-transplant hyperten-
sion [16]. More rare causes of post-transplant hypertension
are the coexistence of a primary aldosteronism, a pheocro-
mocytoma, or hypercalcemia due to a persistent hyperpara-
thyroidism [9].
Whatever the cause of post-transplant hypertension
might be, it seems clear that normal blood pressure is a
good marker of graft survival, and that an effective antihy-
pertensive treatment reduces the progression of graft dam-
age [9]. Even if hypertension was only a consequence and
not the cause of allograft dysfunction, it would still require
therapy because of its known benefit on the cardiac and
cerebral vascular systems [10]. Hypertension is a well-
recognized risk factor for atherosclerotic vascular disease,
which is the leading cause of long-term mortality in renal
transplant patients.
Calcium channel blockers are good antihypertensive
agents, decreasing preglomerular vasoconstriction. In addi-
tion, verapamil can improve cyclosporine nephrotoxicity.
Angiotensin-converting enzyme (ACE) inhibitors have
renoprotective effects, decreasing glomerular overload and
proteinuria. Alpha blockers are effective in controlling high
blood pressure with no metabolic interactions. Based on
the known beneficial effects of these agents in the general
population, the aim of our study was to compare the
long-term efficacy of three different antihypertensive ther-
apies on the outcome of grafts and patients in our kidney
transplant patients, examining the metabolic and general
tolerance of these regimes.
METHODS
Patients
We studied the long-term evolution of 88 renal trans-
plant patients, divided into three groups, all of whom were
under sustained CsA-based immunosuppression. All pa-
tients were hypertensive, as defined by WHO criteria for
patients with some associated risk factors: systolic blood
pressure (SBP) greater than 140 mm Hg or diastolic blood
pressure (DBP) greater than 90 mm Hg.
Table 1 shows the patients’ characteristics. The cause of
end-stage renal failure did not differ in the three groups.
Renal artery stenosis was ruled out based on a Doppler
ultrasonography or a digital subtraction angiography. Pa-
tients in groups I and II were randomized to verapamil or
enalapril, but patients with proteinuria over 1.5 g/day were
included in the enalapril group. At baseline and every three
months thereafter we measured plasma creatinine, total
cholesterol, glycemia, uricemia, hematocrit, CsA levels,
(specific monoclonal RIA), and prednisone doses, as well
as the doses of the different antihypertensive treatments.
The average values of three SBP and DBP measurements
were recorded, and the mean blood pressure was calcu-
lated. Results are expressed at one, two and three years
after treatment.
The patients were initially treated with slow release
verapamil 240 mg/day (group I, N 5 24), enalapril 5 mg/day
(group II, N 5 24), or doxazosin 1 mg/day (group III, N 5
40). The initial doses were increased, and a second or a
third antihypertensive drug was added, depending on blood
pressure control.
Statistics
Statistical analysis was made by applying the Student’s
t-test to within-group measurements and the ANOVA
(analysis of variance) to between-group comparisons.
RESULTS
The three groups of patients had similar baseline char-
acteristics, except that proteinuria was higher in the enala-
pril group (Table 2). Body weight and body mass index
changes were similar in the three groups. Systolic, diastolic
and mean arterial blood pressure decreases were similar in
the three groups over the years (Table 3). Plasma creati-
nine levels at one, two and three years were better in the
doxazosin group, parallel to the lower level of proteinuria,
than in the other two groups (Table 2). CsA levels in-
creased after the introduction of verapamil in this group of
patients, so that CsA doses could be decreased more
rapidly in these patients than in the other two groups.
Hypercholesterolemia was higher at baseline in the
verapamil and the enalapril groups (6.5 6 1.2 in group I,
and 6.56 6 1.2 mmol/liter in group II) than in the doxazo-
sin-treated patients (5.5 6 1.2 mmol/liter). During the
course of the follow-up, 5 patients in the verapamil group,
12 patients in the enalapril group and 13 patients in the
Table 1. Patient characteristics
Group I
(N 5 24)
Group II
(N 5 24)
Group III
(N 5 40)
Age 43 6 8.6 41 6 9.7 44.5 6 11
Sex males 14/10 16/8 24/16
Weight kg body wt 62.4 1 9 68.4 6 14 68 6 11
Height cm 163 6 9 164 6 7 163 6 8
BMI kg body wt/cm2 23.7 6 3 25.3 6 4 25.4 6 4
ESRD cause:
Chronic GN 12 8 16
Polycystic RD 2 5 8
Chronic interstitial nephritis 3 4 6
N. angiosclerosis 3 3 5
Others 4 4 5
Time after transplantation 24 6 12 25 6 13 20 6 12
Acute rejection episodes 3 (16%) 3 (16%) 6 (15%)
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doxazosin group required statins due to persistent hyper-
cholesterolemia above 6.5 mmol/liter. No differences were
seen with regards to uric acid, glucose, hematocrit or
potassium levels. Nevertheless, two enalapril-treated pa-
tients presented with hyperkalemia.
During the course of the follow-up, 7 patients in the
verapamil group, 10 patients in the enalapril group and 15
patients in the doxazosin group required other antihyper-
tensive drugs to control their blood pressure levels. The
higher doses of initial antihipertensive drugs were 480
mg/day of verapamil, 40 mg/day of enalapril and 16 mg/day
of doxazosin (Table 4).
With regards to the side effects of the different medica-
tions, verapamil was well tolerated, but 5 patients (20.8%)
showed side effects (tachycardia, heart failure, relative
hypotension) that forced us to stop the treatment. Enalapril
induced side effects (cough, hyperkalemia, creatinine in-
crease) in five patients (21%). Doxazosin was very well
tolerated with only two patients (5%) requiring treatment
discontinuation due to orthostatic hypotension.
Six patients suffered cardiovascular events during the
follow-up period. Graft survival was higher in doxazosin-
treated patients; only 4 patients (10%) lost the graft, while
5 patients (21%) lost the graft in the verapamil group and
8 patients (33%) lost the graft in the enalapril group. One
patient in the doxazosin group died suddenly (myocardial
infartion?), and one in the enalapril group died from a
hepatobiliary neoplasm.
DISCUSSION
It is likely that evidence of renal protective effects of
specific antihypertensive agents in hypertension in the
general population will apply to transplant patients despite
the differences in the cause of hypertension [10].
In considering the renal effects of antihypertensive treat-
ment, Mountokalakis stresses that several important ques-
tions arise [17]. Should the immediate or medium-term
renal effects of antihypertensive treatment be distinguished
from its long-term effects on renal prognosis? Is the
potentially protective effect determined by changes in the
systemic blood pressure? Can antihypertensive therapy
delay the progression of an underlying renal disease? Does
the ability of the antihypertensive therapy to protect the
kidney depend on the particular antihypertensive agent
used to lower blood pressure? What target blood pressure
is required to preserve renal function?.
The need for a redefinition of a target blood pressure
that would preserve renal function has been suggested by
some authors. Recently, the Joint National Committee for
the Detection, Evaluation and Treatment of High Blood
Pressure recommended a target blood pressure of 135/85
mm Hg or less for patients with renal diseases [18].
Many studies have provided evidence that various anti-
hypertensive agents exert disparate short-term or pro-
longed effects on renal hemodynamics [17]. ACE inhibitors
Table 2. Plasma creatinine, proteinuria, and cyclosporine levels and
doses
Group I Group II Group III
Creatinine mmol/liter
Baseline 196 6 86 178 6 59 183 6 101
1 year 180 6 95 194 6 69 164 6 59
2 years 210 6 142 215 6 117 176 6 69
3 years 265 6 221 193 6 108 194 6 74
Proteinuria g/day
Baseline 0.86 6 0.85 1.73 6 2.2a 0.44 6 0.45
1 year 1.38 6 1.56 1.27 6 1.6 0.4 6 0.5
2 years 1.24 6 1.09 1.57 1 2.03 0.38 6 0.53
3 years 0.98 6 1.4 1.27 6 2.5 1.04 6 2.79
CsA levels g/day
Baseline 181 6 81 156 6 42 181 6 86
1 year 151 6 59 136 6 53 163 6 72
2 years 158 6 39 172 6 101 153 6 60
3 years 141 6 62 144 6 9 123 6 44
CsA doses mg/kg
body wt/day
Baseline 4.5 6 2 4.3 6 1.5 4.9 6 2.7
1 year 3.3 6 1a 4.3 6 1.6 3.7 6 1.6
2 years 3 6 0.6 4.05 6 1.2 3.5 6 1.4
3 years 2.8 6 0.5 4.09 6 1.2 2.6 6 1.3
Specific monoclonal RIA, N 5 100–250 ng/ml.
a P , 0.05.
Table 3. Systolic, diastolic and mean blood pressure results
Group I Group II Group III
Systolic blood pressure
Baseline 171 6 19 166 6 18 168 6 20
1 year 155 6 19a 159 6 18 154 6 19a
2 years 154 6 24a 149 6 19a 145 6 20a
3 years 157 6 12a 149 6 19a 154 6 21a
Diastolic blood pressure
Baseline 106 6 6 100 6 9 97 6 14
1 year 92 6 8a 94 6 13a 88 6 12a
2 years 90 6 13a 88 6 8a 83 6 12a
3 years 92 1 8.7a 84 6 9.8a 90.5 6 16a
Mean blood pressure
Baseline 127 1 7.7 122 6 9.6 121 6 13
1 year 113 6 11a 116 6 14a 110 6 12a
2 years 112 6 15a 108 6 10a 104 6 12a
3 years 113 6 7a 106 6 10a 106 6 29a
a P , 0.05 within-group
P values are not significant between groups.
Table 4. Complications and follow-up
Group I Group II Group III
Treatment discontinued due
to side effects
5 (21%) 5 (21%) 2 (5%)a
Addition of other
antihypertensives
7 10 15
Statin treatment 5 12 13
Cardiovascular events 3 1 2
Treatment follow-up
months
33 6 31 35 6 8 36 6 13
Transplant follow-up
months
85 6 20 91 6 22 59 6 21
Graft loss 8 (33%) 8 (33%) 4 (10%)a
a P , 0.05 Group I and Group II vs. Group III
Martı´nez-Castelao et al: Treatment of post-transplant hypertensionS-132
lower systemic blood pressure and glomerular capillary
pressure, increasing renal blood flow by decreasing post-
glomerular arteriolar tone, that is, efferent vasodilation
[19]. These agents might be more efffective than others in
preventing the progression of renal damage, improved by
additional pharmacological measures and by dietary so-
dium and protein restrictions, considering the risk factor
profile [20].
Increased renal vascular resistance is a prominent fea-
ture of post-transplant hypertension [9, 10]. New agents
that lower blood pressure and increase renal blood flow
could be the ideal drugs to treat hypertension after renal
transplantation. However, it is not clear whether preglo-
merular vessels are primarily affected, or if hypertension
causes glomerular hypertension first and preglomerular
hypertension serves as a secondary protective response
[10]. Diuretics, beta blockers and alpha blockers have had
a significant role in treating hypertension in kidney trans-
plant patients. Often, nonspecific vasodilators and beta
blockers decrease renal blood flow as a response to the
reduction of systemic blood pressure, but it has not yet
been shown whether long-term use of these agents will
result in a poorer outcome than the use of the newer agents
[21]. Since there is evidence that these new agents might
slow the progression of chronic renal failure [22, 23], it is
also possible that they may have a beneficial effect on
chronic rejection.
Theoretically, calcium channel blockers might be a better
choice than ACE inhibitors because they promote dilation
in the afferent arteriole [3], which is the same location
where cyclosporine induces vasoconstriction [24]. However,
calcium channel blockers can frequently cause some unde-
sirable side effects in transplanted patients, such as lower
extremity edema, enhancement of cyclosporine hypertri-
chosis, and gingival hypertrophy.
Verapamil is a very well-known diphenyl-alkylamine
derivative, effective in reducing blood pressure. When used
by intravenous administration it can induce reflex tachycar-
dia, increased cardiac output and peripheral vasoconstric-
tion. It is recognized that verapamil can have a positive
interaction with cyclosporine metabolism, that being the
advantage of decreasing cyclosporine doses, as we have
proven in our patients [25].
In our experience, verapamil was not tolerated in five
patients in the early stage of the treatment. Long-term
tolerance to verapamil has been good, but 8 patients (33%)
in this group lost the graft, which was all due to chronic
transplant nephropathy.
ACE inhibitors are also effective in controlling blood
pressure in renal transplant recipients, and do not interact
with cyclosporine blood levels. Its antiproteinuric effect is
very useful in transplant recipients, so they can act as renal
protective agents. On the negative side, they are associated
with potassium retention. In our patients, ACE inhibitors
caused long-term hyperkalemia and impaired graft func-
tion in 4 patients, and coughing in another. While they are
very useful antihypertensive agents, careful monitoring of
potassium levels and renal function is required, especially
when used in patients with suboptimal graft function.
Regarding the long-term results in our experience, 8 pa-
tients lost the graft in the enalapril-treated group due to
chronic allograft nephropathy, which was the same percent-
age as in the verapamil group.
The blood pressure reduction with both types of agents,
calcium channel blockers and angiotensin-converting en-
zyme inhibitors, is equivalent [26]. If indeed there are no
clinical differences between these two groups of antihyper-
tensive agents, this suggests that preglomerular vasocon-
striction is an essential factor in such hypertension, rather
than glomerular hypoperfusion [9].
These antihypertensive drugs can exert different actions
on proteinuria. Recently, Gansevoort et al examined the
results of 41 trials comparing the antiproteinuric effect of
ACE inhibitors with that of other antihypertensive agents
[27]. It seems that the most important antiproteinuric effect
is conferred by ACE inhibitors, but there is some evidence
that non-dihydropiridine calcium antagonists can decrease
proteinuria regardless of blood pressure changes [28].
Alpha blockers such as doxazosin act by producing a
peripheral vasodilating effect, reducing peripheral resis-
tance and interfering with adrenergic vasoconstrictor
mechanisms without interfering with regional flows, not
decreasing cerebral, cardiac or renal plasma flow [29].
Doxazosin has not induced a deleterious effect on serum
cholesterol and potassium or renal function. It is very well
tolerated, and only orthostatic hypotension may be in-
duced, especially with the first doses.
Patients treated with doxazosin have shown an excellent
tolerance; only two patients were withdrawn from the study
because of relative hypotension. The antihypertensive effi-
cacy of doxazosin has been proven in our patients, but 15
patients in this group required a second antihypertensive
agent. Regarding the long-term graft and patient survival in
the doxazosin group, only 4 patients lost the graft and all of
them were due to chronic transplant nephropathy.
A final comment about the impact of these antihyper-
tensive regimes on the quality of life of hypertensive renal
transplant patients must be added. When new drugs are
compared, no clear advantage has been noted for any
particular class of antihypertensive agent. It does not seem
that calcium channel blockers, ACE inhibitors or alpha
blockers would offer a different profile regarding quality of
life of our hypertensive renal transplant patients.
In summary, the three groups of antihypertensive agents,
ACE inhibitors, calcium channel blockers and alpha block-
ers, are effective in long-term reduction of blood pressure
in renal transplant patients, with no clear advantages of any
one over the others. The CsA-verapamil interaction may
permit a reduction of cyclosporine doses and thus decrease
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the cost of immunosuppression, but calcium channel block-
ers are associated with side effects in a low percentage of
patients. ACE inhibitors offer the possibility to act as renal
protectors, but cough, anemia, hyperkalemia or allograft
function impairment are potential side effects requiring
careful renal function monitoring, especially in cases of
suboptimal renal function. Doxazosin offers an excellent
tolerance profile, being a good alternative in monotherapy
or in association with other antihypertensive drugs, owing
to its safety and efficacy. It seems that doxazosin-treated
patients have a similar long-term outcome as those patients
who are treated with calcium channel blockers or ACE
inhibitors.
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